Advanced PET imaging of cancer for personalized medicine

Molecular imaging has made tremendous progress in the areas of imaging technology, imaging probe and contrast development, data quality, and machine learning-based data analysis. Despite recent technological advances and the availability of dozens of disease-specific contrast agents and imaging probes, few parameters such as tumor size or mean tracer uptake are used in clinical practice to evaluate images.

Our members Johannes Schwenck, Dominik Sonanini, Jonathan Cotton, Hans-Georg Rammensee, Christian la Fougère, Lars Zender & Bernd Pichler did an excellent job in the recent review article in Nature Reviews Cancer. Click here for the article: https://www.nature.com/articles/s41568-023-00576-4?WT.mc_id=TWT_NatureRevCancer